4 papers in the library · 35 citations · publishing 2023-2026
Neuropsychopharmacol Rep September 1, 2026 Daisuke Ibi, Rika Takaba, Keisuke Yoshida et al.
Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress.
International Journal of Neuropsychopharmacology February 1, 2025 *Daisuke Ibi, Rika Takaba, Keisuke Yoshida et al.
Abstract Background Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through the serotonin 5-HT2A receptor (5-HT2A). Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. Aims & Objectives The involvement of...
Naunyn-Schmiedeberg's archives of pharmacology May 1, 2024 Rika Takaba, Daisuke Ibi, Keisuke Yoshida et al. 31 citations
Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the involvement of 5-HT2A in mediating the...
Research Square (Research Square) July 7, 2023 Rika Takaba, Daisuke Ibi, Keisuke Yoshida et al. 4 citations
Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT 2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the involvement of 5-HT2A in...